E-ISSN: 2619-9467

Contents    Cover    Publication Date: 25 Oct 2024
Year 2024 - Volume 34 - Issue 3

Open Access

Peer Reviewed

ORIGINAL RESEARCH
100 Viewed128 Downloaded

Ascites Fluid Interleukin-8 Level as a Predictor of Survival in Patients with Ovarian Cancer: Analytical Research-Cohort Research

Full Text PDF  
JCOG. 2024;34(3):98-105
DOI: 10.5336/jcog.2024-103973
Article Language: EN
Copyright Ⓒ 2024 by Türkiye Klinikleri. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
ABSTRACT
Objective: Ovarian cancer is one of the most fatal gynaecological malignancies worldwide. In ovarian cancer patients, elevated interleukin-8 (IL-8) level was found in ovarian cyst fluid, ascites, serum, and tumour tissue. This study aimed to determine the relation between ascites' IL-8 level and progression-free survival (PFS) as well as overall survival (OS) in ovarian cancer patients. Material and Methods: This prospective cohort included ovarian cancer patients who underwent primary surgery at Sardjito General Hospital during the 2018-2021 period. Samples were taken from ascites fluid. Outcomes including PFS and OS were recorded at the end of this study. IL-8 level was measured with human cytokine magnetic 10-plex panel for luminex (commercial kit invitrogen). Results: The subjects of this study were 40 ovarian cancer patients. The median follow-up was 24 months. During follow-up, 22 participants (55%) were progression-free. Twenty participants (50%) survived at the end of the study. Patients with high IL-8 level significantly had 2.93 times more risk to develop disease progression (p=0.048) and shorter progression free survival time of 15.4 compared to 27.5 months (p log rank 0.02). High IL-8 also decreased OS time of 19.4 compared to 27.3 months but was not significant (p log rank 0.058). Older age significantly related to low overall survival (0% compared to 58.8%), p=0.003. Conclusion: IL-8 ascites increased the risk of disease progression significantly but did not lower overall survival significantly in ovarian cancer. Older age was found to be unbeneficial for overall survival in ovarian cancer patients.
REFERENCES:
  1. Feeney L, Harley IJ, McCluggage WG, Mullan PB, Beirne JP. Liquid biopsy in ovarian cancer: catching the silent killer before it strikes. World J Clin Oncol. 2020;11(11):868-89. [Crossref]  [PubMed]  [PMC] 
  2. Gondhowiardjo S, Christina N, Ganapati NPD, Hawariy S, Radityamurti F, Jayalie VF, et al. Five-year cancer epidemiology at the national referral hospital: hospital-based cancer registry data in indonesia. JCO Glob Oncol. 2021;7:190-203. [Crossref]  [PubMed]  [PMC] 
  3. Köbel M, Kalloger SE, Lee S, Duggan MA, Kelemen LE, Prentice L, et al; Ovarian Tumor Tissue Analysis consortium. Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomarkers Prev. 2013;22(10):1677-86. [Crossref]  [PubMed]  [PMC] 
  4. Ali AT. Towards prevention of ovarian cancer. Curr Cancer Drug Targets. 2018;18(6):522-37. [Crossref]  [PubMed] 
  5. Roebuck KA. Regulation of interleukin-8 gene expression. J Interferon Cytokine Res. 1999;19(5):429-38. [Crossref]  [PubMed] 
  6. Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer. 2000;10(1):33-41. [Crossref]  [PubMed] 
  7. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001;12(4):375-91. [Crossref]  [PubMed] 
  8. Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H, Miyasaka M. Chemokines in tumor progression and metastasis. Cancer Sci. 2005;96(6):317-22. Erratum in: Cancer Sci. 2005;96(8):534. Yang, Bogi [corrected to Yang, Bo-Gie]. [Crossref]  [PubMed]  [PMC] 
  9. Wang Y, Xu RC, Zhang XL, Niu XL, Qu Y, Li LZ, et al. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine. 2012;59(1):145-55. [Crossref]  [PubMed] 
  10. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1982;1(2):121-9. [Crossref]  [PubMed] 
  11. Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T, Azzam Eel-D, et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem. 2004;37(5):363-9. [Crossref]  [PubMed] 
  12. Galic Jerman K, Kobal B, Jakimovska M, Verdenik I, Cerne K. Control values of ovarian cancer tumor markers and standardisation of a protocol for sampling peritoneal fluid and performing washing during laparoscopy. World J Surg Oncol. 2014;12:278. [Crossref]  [PubMed]  [PMC] 
  13. Lane D, Matte I, Rancourt C, Piché A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer. 2011;11:210. [Crossref]  [PubMed]  [PMC] 
  14. Kurman RJ, Shih IeM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733-47. [Crossref]  [PubMed]  [PMC] 
  15. Polterauer S, Vergote I, Concin N, Braicu I, Chekerov R, Mahner S, et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. Int J Gynecol Cancer. 2012;22(3):380-5. [Crossref]  [PubMed] 
  16. Sangisetty SL, Miner TJ. Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg. 2012;4(4):87-95. [Crossref]  [PubMed]  [PMC] 
  17. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol. 2017;24(6):311-35. [Crossref]  [PubMed]  [PMC] 
  18. Chen M, Jin Y, Bi Y, Li Y, Shan Y, Pan L. Prognostic significance of lymphovascular space invasion in epithelial ovarian cancer. J Cancer. 2015;6(5):412-9. [Crossref]  [PubMed]  [PMC] 
  19. Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, Kulesza-Bronczyk B, Kinalski M, Terlikowski SJ. Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer. Eur Cytokine Netw. 2013;24(3):106-13. [Crossref]  [PubMed] 
  20. Aune G, Stunes AK, Lian AM, Reseland JE, Tingulstad S, Torp SH, et al. Circulating interleukin-8 and plasminogen activator inhibitor-1 are increased in women with ovarian carcinoma. Results Immunol. 2012;2:190-5. [Crossref]  [PubMed]  [PMC] 
  21. Zhang L, Liu W, Wang X, Wang X, Sun H. Prognostic value of serum IL-8 and IL-10 in patients with ovarian cancer undergoing chemotherapy. Oncol Lett. 2019;17(2):2365-9. [Crossref]  [PubMed]  [PMC] 
  22. Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer. 2020;123(1):9-16. [Crossref]  [PubMed]  [PMC] 
  23. Wang Y, Yang J, Gao Y, Dong LJ, Liu S, Yao Z. Reciprocal regulation of 5alpha-dihydrotestosterone, interleukin-6 and interleukin-8 during proliferation of epithelial ovarian carcinoma. Cancer Biol Ther. 2007;6(6):864-71. [Crossref]  [PubMed] 
  24. Lokshin AE, Winans M, Landsittel D, Marrangoni AM, Velikokhatnaya L, Modugno F, et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol. 2006;102(2):244-51. [Crossref]  [PubMed] 
  25. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008;100(5):359-72. [Crossref]  [PubMed]  [PMC] 
  26. Viral P, Rajanbabu A, Pavithran K, Chithrathara K, Nair IR, Bhaskaran R, et al. Long-term survival outcome of advanced epithelial ovarian cancer: a single institutional study. Indian J Cancer. 2021;58(3):342-8. [Crossref]  [PubMed] 
  27. Yang L, Klint A, Lambe M, Bellocco R, Riman T, Bergfeldt K, et al. Predictors of ovarian cancer survival: a population-based prospective study in Sweden. Int J Cancer. 2008;123(3):672-9. [Crossref]  [PubMed] 
  28. Chan JK, Urban R, Cheung MK, Osann K, Shin JY, Husain A, et al. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer. 2006;95(10):1314-20. Erratum in: Br J Cancer. 2007;96(3):534. Shin, J Y [added]. Erratum in: Br J Cancer. 2007;96(9):1492. [Crossref]  [PubMed]  [PMC] 
  29. Duska LR, Tew WP, Moore KN. Epithelial ovarian cancer in older women: defining the best management approach. Am Soc Clin Oncol Educ Book. 2015:e311-21. [Crossref]  [PubMed] 
  30. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287-99. [Crossref]  [PubMed]  [PMC] 
  31. Rousseau F, Ranchon F, Bardin C, Bakrin N, Lavoué V, Bengrine-Lefevre L, et al. Ovarian cancer in the older patient: where are we now? What to do next? Ther Adv Med Oncol. 2023;15:17588359231192397. [Crossref]  [PubMed]  [PMC] 
  32. Gershenson DM. The life and times of low-grade serous carcinoma of the ovary. Am Soc Clin Oncol Educ Book. 2013. [Crossref]  [PubMed] 
  33. Wang X, Wang S, Yao S, Shi W, Ma K. The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review. J Ovarian Res. 2022;15(1):104. [Crossref]  [PubMed]  [PMC] 
  34. van de Kruis N, van der Ploeg P, Wilting JHC, Caroline Vos M, Thijs AMJ, de Hullu J, et al. The progression-free survival ratio as outcome measure in recurrent ovarian carcinoma patients: current and future perspectives. Gynecol Oncol Rep. 2022;42:101035. [Crossref]  [PubMed]  [PMC] 
  35. Arora T, Mullangi S, Lekkala MR. Ovarian Cancer. [Updated 2023 Jun 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: [Link]